OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
Sophie M. Ernst, Ronald van Marion, Peggy N Atmodimedjo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 995-1006
Closed Access | Times Cited: 14
Sophie M. Ernst, Ronald van Marion, Peggy N Atmodimedjo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 995-1006
Closed Access | Times Cited: 14
Showing 14 citing articles:
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Linyan Tian, Chengming Liu, Sufei Zheng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Linyan Tian, Chengming Liu, Sufei Zheng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients
Guillaume Herbreteau, M. Marcq, Chloé Sauzay, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 783-783
Open Access
Guillaume Herbreteau, M. Marcq, Chloé Sauzay, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 783-783
Open Access
Pretreatment Liquid Biopsy and Clinicopathologic Features in HPV−Associated Oropharyngeal Squamous Cell Carcinoma
Peter V. Cooke, Susmita Chennareddy, Daniel O. Kraft, et al.
JAMA Otolaryngology–Head & Neck Surgery (2025)
Closed Access
Peter V. Cooke, Susmita Chennareddy, Daniel O. Kraft, et al.
JAMA Otolaryngology–Head & Neck Surgery (2025)
Closed Access
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
Sophie M. Ernst, Mihaela Aldea, Jan H. von der Thüsen, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Sophie M. Ernst, Mihaela Aldea, Jan H. von der Thüsen, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3788-3797
Open Access | Times Cited: 4
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3788-3797
Open Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives
Paul Hofman
Cancers (2024) Vol. 16, Iss. 19, pp. 3340-3340
Open Access | Times Cited: 1
Paul Hofman
Cancers (2024) Vol. 16, Iss. 19, pp. 3340-3340
Open Access | Times Cited: 1
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Ateş Kutay Tenekeci, A. Unal, Furkan Ceylan, et al.
Future Oncology (2024) Vol. 20, Iss. 37, pp. 3019-3038
Closed Access | Times Cited: 1
Ateş Kutay Tenekeci, A. Unal, Furkan Ceylan, et al.
Future Oncology (2024) Vol. 20, Iss. 37, pp. 3019-3038
Closed Access | Times Cited: 1
Exploring the use of circulating tumor DNA for mutational signature analysis
Sophie M. Ernst, Ronald van Marion, Jan H. von der Thüsen, et al.
Lung Cancer (2024) Vol. 193, pp. 107844-107844
Closed Access
Sophie M. Ernst, Ronald van Marion, Jan H. von der Thüsen, et al.
Lung Cancer (2024) Vol. 193, pp. 107844-107844
Closed Access
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”
N Kosaka, Yuki Kataoka
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. e28-e28
Closed Access
N Kosaka, Yuki Kataoka
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. e28-e28
Closed Access
Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”
Yanfang Jiang, Lei Zhang
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 9, pp. e43-e43
Closed Access
Yanfang Jiang, Lei Zhang
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 9, pp. e43-e43
Closed Access
Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?
Anna Fabisiewicz, Małgorzata Szostakowska-Rodzoś, Ewa A. Grzybowska
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10612-10612
Open Access
Anna Fabisiewicz, Małgorzata Szostakowska-Rodzoś, Ewa A. Grzybowska
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10612-10612
Open Access
Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result
Yaping Hong, Wu Zhuang, Jinhuo Lai, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Yaping Hong, Wu Zhuang, Jinhuo Lai, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
